Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals (NASDAQ: KALV) has achieved two significant milestones in Japan for sebetralstat, its investigational oral treatment for hereditary angioedema (HAE) attacks. The company received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare and submitted a New Drug Application (NDA) for the medication.
If approved, sebetralstat would become the first oral on-demand treatment for HAE in Japan, targeting adults and adolescents aged 12 years and older. The drug is a novel plasma kallikrein inhibitor, and its NDA submission is supported by data from the KONFIDENT phase 3 clinical trial and ongoing KONFIDENT-S open-label extension trial.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced new inducement grants for recently hired employees. On January 2, 2025, nine new employees were granted options to purchase a total of 61,000 shares of KalVista common stock. Additionally, on January 6, 2025, one new employee received options to purchase 50,000 shares.
The options' exercise price equals the closing price of KalVista stock on their respective grant dates. The vesting schedule includes 25% after one year, with the remaining portions vesting monthly over three years, contingent on continued employment. All options have a 10-year term and are governed by KalVista's Amended and Restated 2021 Equity Inducement Plan, granted under Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) has appointed Jeb Ledell as Chief Operating Officer. Ledell brings over 20 years of biotechnology industry leadership experience, joining from AVEO Oncology. His previous roles include COO positions at Enzyvant Therapeutics, where he contributed to RETHYMIC®'s FDA approval, and leadership positions at Compass Therapeutics and Horizon Discovery Group.
As part of his employment agreement, Ledell received inducement options for 100,000 shares of Common Stock, with an exercise price equal to the closing price on December 16, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.
KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 fiscal 2024 results and provided updates on sebetralstat, its investigational oral treatment for hereditary angioedema (HAE) attacks. The FDA accepted the New Drug Application with a PDUFA date of June 17, 2025. The company submitted Marketing Authorization Applications in multiple countries.
Financial highlights include pro forma cash and equivalents of $292.2 million, providing runway into second half 2027. The company raised $160 million through synthetic royalty financing and equity offerings. Q2 showed no revenue, R&D expenses of $16.6 million (down from $19.1 million), and G&A expenses of $29.2 million (up from $10.7 million) primarily due to pre-commercial activities.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to five newly-hired employees. The compensation committee approved options to purchase 36,000 shares of common stock at an exercise price of $10.27 per share, matching the closing price on December 2, 2024. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years, contingent on continued employment. These 10-year term options were granted under KalVista's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) announced the appointment of Laurence Reid, Ph.D., to its Board of Directors, effective immediately. Dr. Reid brings over three decades of experience in biotech leadership and company-building. KalVista CEO Ben Palleiko highlighted Dr. Reid's biopharmaceutical and strategic expertise as a significant asset for advancing sebetralstat towards global market approval and commercialization. Dr. Reid expressed enthusiasm for joining at a pivotal time, noting sebetralstat's potential to improve lives of hereditary angioedema patients. Dr. Reid's previous roles include CEO of Decibel Therapeutics, entrepreneur in residence at Third Rock Ventures, and CEO of Warp Drive Bio. He currently chairs the board of Broken String Biosciences and holds board positions at Garuda Therapeutics and The Possible Zone.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced its participation in two upcoming investor conferences. The company will engage in fireside chats at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST, and the Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT.
Both presentations will be available via live webcast on KalVista's website, with audio archives remaining accessible for 30 days following the events.
KalVista Pharmaceuticals (NASDAQ: KALV) announced that its compensation committee has granted stock options to twelve newly-hired employees. The inducement grants total 78,000 shares of common stock with an exercise price of $10.61 per share, matching the closing price on November 1, 2024. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years, contingent on continued employment. These 10-year term options were granted under KalVista's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (KALV) has announced the pricing of an underwritten offering of 5.5 million shares at $10.00 per share, expecting to raise $55 million. Concurrently, the company entered a private placement agreement with DRI Healthcare Acquisitions LP for an additional 500,000 shares at the same price, raising an additional $5 million. The proceeds will fund the clinical development of sebetralstat and its planned commercialization. The offerings are expected to close on November 5, 2024, with Jefferies, BofA Securities, TD Cowen, and Stifel acting as joint book-running managers.
KalVista Pharmaceuticals (NASDAQ: KALV) has secured a synthetic royalty financing agreement with DRI Healthcare Trust worth up to $184 million to support the commercial launch of sebetralstat, potentially the first oral on-demand therapy for hereditary angioedema (HAE). The deal includes a $100 million upfront payment, an optional $22 million payment upon U.S. approval, and up to $57 million in sales-based milestones. The FDA has set a PDUFA target date of June 17, 2025. Under the agreement, KalVista will pay DRI tiered royalties ranging from 0.25% to 5.00% based on annual global net sales thresholds. DRI has also expressed interest in a potential $5 million equity investment in KalVista.
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
What is the market cap of KalVista Pharmaceuticals (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
